Canada · Delayed Price · Currency is CAD InnoCan Pharma Statistics
Total Valuation
InnoCan Pharma has a market cap or net worth of CAD 28.43 million. The enterprise value is 24.16 million.
| Market Cap | 28.43M |
| Enterprise Value | 24.16M |
Important Dates
The last earnings date was Tuesday, April 14, 2026.
| Earnings Date | Apr 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoCan Pharma has 4.50 million shares outstanding. The number of shares has increased by 3.92% in one year.
| Current Share Class | 4.50M |
| Shares Outstanding | 4.50M |
| Shares Change (YoY) | +3.92% |
| Shares Change (QoQ) | -0.41% |
| Owned by Insiders (%) | 3.41% |
| Owned by Institutions (%) | n/a |
| Float | 3.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.78 |
| PB Ratio | 2.52 |
| P/TBV Ratio | 3.70 |
| P/FCF Ratio | 43.29 |
| P/OCF Ratio | 41.89 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -15.67 |
| EV / Sales | 0.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 36.78 |
Financial Position
The company has a current ratio of 7.70, with a Debt / Equity ratio of 0.11.
| Current Ratio | 7.70 |
| Quick Ratio | 5.63 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.94 |
| Interest Coverage | -418.37 |
Financial Efficiency
Return on equity (ROE) is -4.47% and return on invested capital (ROIC) is 299.24%.
| Return on Equity (ROE) | -4.47% |
| Return on Assets (ROA) | -7.93% |
| Return on Invested Capital (ROIC) | 299.24% |
| Return on Capital Employed (ROCE) | -13.69% |
| Weighted Average Cost of Capital (WACC) | 3.26% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 5 |
| Asset Turnover | 2.69 |
| Inventory Turnover | 0.98 |
Taxes
In the past 12 months, InnoCan Pharma has paid 584,097 in taxes.
| Income Tax | 584,097 |
| Effective Tax Rate | 501.18% |
Stock Price Statistics
The stock price has decreased by -45.98% in the last 52 weeks. The beta is -0.14, so InnoCan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.14 |
| 52-Week Price Change | -45.98% |
| 50-Day Moving Average | 7.23 |
| 200-Day Moving Average | 11.85 |
| Relative Strength Index (RSI) | 41.24 |
| Average Volume (20 Days) | 1,682 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCan Pharma had revenue of CAD 36.49 million and -1.54 million in losses. Loss per share was -0.34.
| Revenue | 36.49M |
| Gross Profit | 32.81M |
| Operating Income | -1.72M |
| Pretax Income | 116,545 |
| Net Income | -1.54M |
| EBITDA | -1.66M |
| EBIT | -1.72M |
| Loss Per Share | -0.34 |
Balance Sheet
The company has 9.17 million in cash and 1.28 million in debt, with a net cash position of 7.89 million or 1.75 per share.
| Cash & Cash Equivalents | 9.17M |
| Total Debt | 1.28M |
| Net Cash | 7.89M |
| Net Cash Per Share | 1.75 |
| Equity (Book Value) | 11.29M |
| Book Value Per Share | 1.71 |
| Working Capital | 12.45M |
Cash Flow
In the last 12 months, operating cash flow was 678,704 and capital expenditures -21,938, giving a free cash flow of 656,766.
| Operating Cash Flow | 678,704 |
| Capital Expenditures | -21,938 |
| Depreciation & Amortization | 57,396 |
| Net Borrowing | 859,573 |
| Free Cash Flow | 656,766 |
| FCF Per Share | 0.15 |
Margins
Gross margin is 89.93%, with operating and profit margins of -4.72% and -4.22%.
| Gross Margin | 89.93% |
| Operating Margin | -4.72% |
| Pretax Margin | 0.32% |
| Profit Margin | -4.22% |
| EBITDA Margin | -4.56% |
| EBIT Margin | -4.72% |
| FCF Margin | 1.80% |
Dividends & Yields
InnoCan Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.92% |
| Shareholder Yield | -3.92% |
| Earnings Yield | -5.42% |
| FCF Yield | 2.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 5, 2025. It was a reverse split with a ratio of 0.015384615.
| Last Split Date | Sep 5, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.015384615 |
Scores
InnoCan Pharma has an Altman Z-Score of 9.38 and a Piotroski F-Score of 4.
| Altman Z-Score | 9.38 |
| Piotroski F-Score | 4 |